1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Type (2022-2028) 1.2.2 Tablet 1.2.3 Injection 1.3 Market by Application 1.3.1 Global Specific Antiviral Drugs for COVID-19 Market Share by Application (2022-2028) 1.3.2 Mild Symptom Patient 1.3.3 Critically Ill Patient 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Specific Antiviral Drugs for COVID-19 Market Size 2.2 Specific Antiviral Drugs for COVID-19 Market Size by Regions 2.2.1 Specific Antiviral Drugs for COVID-19 Growth Rate by Regions (2022-2028) 2.2.2 Specific Antiviral Drugs for COVID-19 Market Share by Regions (2022-2028) 2.3 Industry Trends 2.3.1 Market Top Trends 2.3.2 Market Use Cases 3 Key Players 3.1 Specific Antiviral Drugs for COVID-19 Revenue by Players (2022 & 2028) 3.2 Specific Antiviral Drugs for COVID-19 Key Players Headquarters and Area Served 3.3 Key Players Specific Antiviral Drugs for COVID-19 Product/Solution/Service 3.4 Date of Enter into Specific Antiviral Drugs for COVID-19 Market 3.5 Mergers & Acquisitions, Expansion Plans 4 Breakdown by Type and by Application 4.1 Global Specific Antiviral Drugs for COVID-19 Market Size by Type (2022-2028) 4.2 Global Specific Antiviral Drugs for COVID-19 Market Size by Application (2022-2028) 5 North America 5.1 North America Specific Antiviral Drugs for COVID-19 Market Forecast (2022-2028) 5.2 Specific Antiviral Drugs for COVID-19 Key Players in North America 5.3 North America Specific Antiviral Drugs for COVID-19 Market Size by Type 5.4 North America Specific Antiviral Drugs for COVID-19 Market Size by Application 6 Europe 6.1 Europe Specific Antiviral Drugs for COVID-19 Market Forecast (2022-2028) 6.2 Specific Antiviral Drugs for COVID-19 Key Players in Europe 6.3 Europe Specific Antiviral Drugs for COVID-19 Market Size by Type 6.4 Europe Specific Antiviral Drugs for COVID-19 Market Size by Application 7 Asia-Pacific 7.1 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Forecast (2022-2028) 7.2 Specific Antiviral Drugs for COVID-19 Key Players in Asia-Pacific 7.3 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Type 7.4 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Application 8 Rest of World 8.1 Latin America 8.1.1 Latin America Specific Antiviral Drugs for COVID-19 Market Analysis 8.1.2 Key Players in Latin America 8.2 Middle East & Africa 8.2.1 Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Analysis 8.2.2 Key Players in Middle East & Africa 9 International Player Profiles 9.1 Sanofi 9.1.1 Sanofi Company Details 9.1.2 Sanofi Description and Business Overview 9.1.3 Sanofi Specific Antiviral Drugs for COVID-19 Introduction 9.1.4 Sanofi Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.1.5 Sanofi Recent Development 9.2 Novartis 9.2.1 Novartis Company Details 9.2.2 Novartis Description and Business Overview 9.2.3 Novartis Specific Antiviral Drugs for COVID-19 Introduction 9.2.4 Novartis Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.2.5 Novartis Recent Development 9.3 Shanghai Zhongxisanwei 9.3.1 Shanghai Zhongxisanwei Company Details 9.3.2 Shanghai Zhongxisanwei Description and Business Overview 9.3.3 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Introduction 9.3.4 Shanghai Zhongxisanwei Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.3.5 Shanghai Zhongxisanwei Recent Development 9.4 Teva 9.4.1 Teva Company Details 9.4.2 Teva Description and Business Overview 9.4.3 Teva Specific Antiviral Drugs for COVID-19 Introduction 9.4.4 Teva Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.4.5 Teva Recent Development 9.5 Zydus Cadila 9.5.1 Zydus Cadila Company Details 9.5.2 Zydus Cadila Description and Business Overview 9.5.3 Zydus Cadila Specific Antiviral Drugs for COVID-19 Introduction 9.5.4 Zydus Cadila Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.5.5 Zydus Cadila Recent Development 9.6 Mylan 9.6.1 Mylan Company Details 9.6.2 Mylan Description and Business Overview 9.6.3 Mylan Specific Antiviral Drugs for COVID-19 Introduction 9.6.4 Mylan Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.6.5 Mylan Recent Development 9.7 Apotex 9.7.1 Apotex Company Details 9.7.2 Apotex Description and Business Overview 9.7.3 Apotex Specific Antiviral Drugs for COVID-19 Introduction 9.7.4 Apotex Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.7.5 Apotex Recent Development 9.8 Advanz Pharma 9.8.1 Advanz Pharma Company Details 9.8.2 Advanz Pharma Description and Business Overview 9.8.3 Advanz Pharma Specific Antiviral Drugs for COVID-19 Introduction 9.8.4 Advanz Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.8.5 Advanz Pharma Recent Development 9.9 Sun Pharma 9.9.1 Sun Pharma Company Details 9.9.2 Sun Pharma Description and Business Overview 9.9.3 Sun Pharma Specific Antiviral Drugs for COVID-19 Introduction 9.9.4 Sun Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.9.5 Sun Pharma Recent Development 9.10 Kyung Poong 9.10.1 Kyung Poong Company Details 9.10.2 Kyung Poong Description and Business Overview 9.10.3 Kyung Poong Specific Antiviral Drugs for COVID-19 Introduction 9.10.4 Kyung Poong Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.10.5 Kyung Poong Recent Development 9.11 Ipca Laboratories 9.11.1 Ipca Laboratories Company Details 9.11.2 Ipca Laboratories Description and Business Overview 9.11.3 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Introduction 9.11.4 Ipca Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.11.5 Ipca Laboratories Recent Development 9.12 Hanlim Pharmaceutical 9.12.1 Hanlim Pharmaceutical Company Details 9.12.2 Hanlim Pharmaceutical Description and Business Overview 9.12.3 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction 9.12.4 Hanlim Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.12.5 Hanlim Pharmaceutical Recent Development 9.13 Bristol Laboratories 9.13.1 Bristol Laboratories Company Details 9.13.2 Bristol Laboratories Description and Business Overview 9.13.3 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Introduction 9.13.4 Bristol Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.13.5 Bristol Laboratories Recent Development 9.14 Bayer 9.14.1 Bayer Company Details 9.14.2 Bayer Description and Business Overview 9.14.3 Bayer Specific Antiviral Drugs for COVID-19 Introduction 9.14.4 Bayer Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.14.5 Bayer Recent Development 9.15 Rising Pharmaceutical 9.15.1 Rising Pharmaceutical Company Details 9.15.2 Rising Pharmaceutical Description and Business Overview 9.15.3 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction 9.15.4 Rising Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.15.5 Rising Pharmaceutical Recent Development 9.16 Shanghai Pharma 9.16.1 Company Details 9.16.2 Shanghai Pharma Description and Business Overview 9.16.3 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Introduction 9.16.4 Shanghai Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.16.5 Shanghai Pharma Recent Development 9.17 Sichuan Sunny Hope 9.17.1 Sichuan Sunny Hope Company Details 9.17.2 Sichuan Sunny Hope Description and Business Overview 9.17.3 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Introduction 9.17.4 Sichuan Sunny Hope Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.17.5 Sichuan Sunny Hope Recent Development 9.18 Guangzhou Baiyunshan Guanghua Pharmaceutical 9.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Company Details 9.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Description and Business Overview 9.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction 9.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.18.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Development 9.19 CSPC Group 9.19.1 CSPC Group Company Details 9.19.2 CSPC Group Description and Business Overview 9.19.3 CSPC Group Specific Antiviral Drugs for COVID-19 Introduction 9.19.4 CSPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.19.5 CSPC Group Recent Development 9.20 KPC Group 9.20.1 KPC Group Company Details 9.20.2 KPC Group Description and Business Overview 9.20.3 KPC Group Specific Antiviral Drugs for COVID-19 Introduction 9.20.4 KPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.20.5 KPC Group Recent Development 9.21 Jinghua Pharmaceutical Group 9.21.1 Jinghua Pharmaceutical Group Company Details 9.21.2 Jinghua Pharmaceutical Group Description and Business Overview 9.21.3 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Introduction 9.21.4 Jinghua Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.21.5 Jinghua Pharmaceutical Group Recent Development 9.22 Zhongsheng Pharma 9.22.1 Zhongsheng Pharma Company Details 9.22.2 Zhongsheng Pharma Description and Business Overview 9.22.3 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Introduction 9.22.4 Zhongsheng Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.22.5 Zhongsheng Pharma Recent Development 9.23 North China Pharmaceutical Group 9.23.1 North China Pharmaceutical Group Company Details 9.23.2 North China Pharmaceutical Group Description and Business Overview 9.23.3 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Introduction 9.23.4 North China Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2022 & 2028) 9.23.5 North China Pharmaceutical Group Recent Development 10 Market Dynamics 10.1 Industry Trends 10.2 Market Drives 10.3 Market Challenges 10.4 Market Restraints 11 Key Findings in This Report 12 Appendix 12.1 Research Methodology 12.1.1 Methodology/Research Approach 12.1.2 Data Source 12.2 Disclaimer 12.3 Author Details

List of Tables Table 1. Global Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Type (2022-2028) (US$ Million) Table 2. Key Players of Tablet Table 3. Key Players of Injection Table 4. Global Specific Antiviral Drugs for COVID-19 Market Size Growth by Application (2022-2028) (US$ Million) Table 5. Global Specific Antiviral Drugs for COVID-19 Market Size by Regions (2022-2028) (US$ Million) Table 6. Global Specific Antiviral Drugs for COVID-19 Market Share by Regions (2022-2028) Table 7. Market Top Trends Table 8. Market Use Cases Table 9. Global Specific Antiviral Drugs for COVID-19 Revenue by Players (2022 & 2028) (US$ Million) Table 10. Global Specific Antiviral Drugs for COVID-19 Market Share by Players (2022 &2028) Table 11. Key Players Headquarters and Area Served Table 12. Key Players Specific Antiviral Drugs for COVID-19 Product/Solution/Service Table 13. Date of Enter into Specific Antiviral Drugs for COVID-19 Market Table 14. Mergers & Acquisitions, Expansion Plans Table 15. Global Specific Antiviral Drugs for COVID-19 Market Size by Type (2022-2028) (US$ Million) Table 16. Global Specific Antiviral Drugs for COVID-19 Market Size Share by Type (2022-2028) Table 17. Global Specific Antiviral Drugs for COVID-19 Market Size by Application (2022-2028) (US$ Million) Table 18. Global Specific Antiviral Drugs for COVID-19 Market Size Share by Application (2022-2028) Table 19. North America Key Players Specific Antiviral Drugs for COVID-19 Revenue (2022 & 2028) & (US$ Million) Table 20. North America Key Players Specific Antiviral Drugs for COVID-19 Market Share (2022 & 2028) Table 21. North America Specific Antiviral Drugs for COVID-19 Market Size by Type (2022-2028) (US$ Million) Table 22. North America Specific Antiviral Drugs for COVID-19 Market Share by Type (2022-2028) Table 23. North America Specific Antiviral Drugs for COVID-19 Market Size by Application (2022-2028) (US$ Million) Table 24. North America Specific Antiviral Drugs for COVID-19 Market Share by Application (2022-2028) Table 25. Europe Key Players Specific Antiviral Drugs for COVID-19 Revenue (2022 & 2028) & (US$ Million) Table 26. Europe Key Players Specific Antiviral Drugs for COVID-19 Market Share (2022 & 2028) Table 27. Europe Specific Antiviral Drugs for COVID-19 Market Size by Type (2022-2028) (US$ Million) Table 28. Europe Specific Antiviral Drugs for COVID-19 Market Share by Type (2022-2028) Table 29. Europe Specific Antiviral Drugs for COVID-19 Market Size by Application (2022-2028) (US$ Million) Table 30. Europe Specific Antiviral Drugs for COVID-19 Market Share by Application (2022-2028) Table 31. Asia-Pacific Key Players Specific Antiviral Drugs for COVID-19 Revenue (2022 & 2028) & (US$ Million) Table 32. Asia-Pacific Key Players Specific Antiviral Drugs for COVID-19 Market Share (2022 & 2028) Table 33. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Type (2022-2028) (US$ Million) Table 34. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Share by Type (2022-2028) Table 35. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Application (2022-2028) (US$ Million) Table 36. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Share by Application (2022-2028) Table 37. Key Players in Latin America Table 38. Key Players in Middle East & Africa Table 39. Sanofi Company Details Table 40. Sanofi Description and Business Overview Table 41. Sanofi Specific Antiviral Drugs for COVID-19 Product Table 42. Sanofi Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 43. Sanofi Recent Development Table 44. Novartis Company Details Table 45. Novartis Description and Business Overview Table 46. Novartis Specific Antiviral Drugs for COVID-19 Product Table 47. Novartis Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 48. Novartis Recent Development Table 49. Shanghai Zhongxisanwei Company Details Table 50. Shanghai Zhongxisanwei Description and Business Overview Table 51. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Product Table 52. Shanghai Zhongxisanwei Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 53. Shanghai Zhongxisanwei Recent Development Table 54. Teva Company Details Table 55. Teva Description and Business Overview Table 56. Teva Specific Antiviral Drugs for COVID-19 Product Table 57. Teva Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 58. Teva Recent Development Table 59. Zydus Cadila Company Details Table 60. Zydus Cadila Description and Business Overview Table 61. Zydus Cadila Specific Antiviral Drugs for COVID-19 Product Table 62. Zydus Cadila Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 63. Zydus Cadila Recent Development Table 64. Mylan Company Details Table 65. Mylan Description and Business Overview Table 66. Mylan Specific Antiviral Drugs for COVID-19 Product Table 67. Mylan Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 68. Mylan Recent Development Table 69. Apotex Company Details Table 70. Apotex Description and Business Overview Table 71. Apotex Specific Antiviral Drugs for COVID-19 Product Table 72. Apotex Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 73. Apotex Recent Development Table 74. Advanz Pharma Company Details Table 75. Advanz Pharma Description and Business Overview Table 76. Advanz Pharma Specific Antiviral Drugs for COVID-19 Product Table 77. Advanz Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 78. Advanz Pharma Recent Development Table 79. Sun Pharma Company Details Table 80. Sun Pharma Description and Business Overview Table 81. Sun Pharma Specific Antiviral Drugs for COVID-19 Product Table 82. Sun Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 83. Sun Pharma Recent Development Table 84. Kyung Poong Company Details Table 85. Kyung Poong Description and Business Overview Table 86. Kyung Poong Specific Antiviral Drugs for COVID-19 Product Table 87. Kyung Poong Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 88. Kyung Poong Recent Development Table 89. Ipca Laboratories Company Details Table 90. Ipca Laboratories Description and Business Overview Table 91. Ipca Laboratories Specific Antiviral Drugs for COVID-19 Product Table 92. Ipca Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 93. Ipca Laboratories Recent Development Table 94. Hanlim Pharmaceutical Company Details Table 95. Hanlim Pharmaceutical Description and Business Overview Table 96. Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Table 97. Hanlim Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 98. Hanlim Pharmaceutical Recent Development Table 99. Bristol Laboratories Company Details Table 100. Bristol Laboratories Description and Business Overview Table 101. Bristol Laboratories Specific Antiviral Drugs for COVID-19 Product Table 102. Bristol Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 103. Bristol Laboratories Recent Development Table 104. Bayer Company Details Table 105. Bayer Description and Business Overview Table 106. Bayer Specific Antiviral Drugs for COVID-19 Product Table 107. Bayer Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 108. Bayer Recent Development Table 109. Rising Pharmaceutical Company Details Table 110. Rising Pharmaceutical Description and Business Overview Table 111. Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Table 112. Rising Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 113. Rising Pharmaceutical Recent Development Table 114. Shanghai Pharma Company Details Table 115. Shanghai Pharma Description and Business Overview Table 116. Shanghai Pharma Specific Antiviral Drugs for COVID-19 Product Table 117. Shanghai Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 118. Shanghai Pharma Recent Development Table 119. Sichuan Sunny Hope Company Details Table 120. Sichuan Sunny Hope Description and Business Overview Table 121. Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Product Table 122. Sichuan Sunny Hope Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 123. Sichuan Sunny Hope Recent Development Table 124. Guangzhou Baiyunshan Guanghua Pharmaceutical Company Details Table 125. Guangzhou Baiyunshan Guanghua Pharmaceutical Description and Business Overview Table 126. Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Product Table 127. Guangzhou Baiyunshan Guanghua Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 128. Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Development Table 129. CSPC Group Company Details Table 130. CSPC Group Description and Business Overview Table 131. CSPC Group Specific Antiviral Drugs for COVID-19 Product Table 132. CSPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 133. CSPC Group Recent Development Table 134. KPC Group Company Details Table 135. KPC Group Description and Business Overview Table 136. KPC Group Specific Antiviral Drugs for COVID-19 Product Table 137. KPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 138. KPC Group Recent Development Table 139. Jinghua Pharmaceutical Group Company Details Table 140. Jinghua Pharmaceutical Group Description and Business Overview Table 141. Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Table 142. Jinghua Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 143. Jinghua Pharmaceutical Group Recent Development Table 144. Zhongsheng Pharma Company Details Table 145. Zhongsheng Pharma Description and Business Overview Table 146. Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Product Table 147. Zhongsheng Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 148. Zhongsheng Pharma Recent Development Table 149. North China Pharmaceutical Group Company Details Table 150. North China Pharmaceutical Group Description and Business Overview Table 151. North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product Table 152. North China Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business 2022 & 2028 Table 153. North China Pharmaceutical Group Recent Development Table 154. Specific Antiviral Drugs for COVID-19 Market Trends Table 155. Specific Antiviral Drugs for COVID-19 Market Drivers Table 156. Specific Antiviral Drugs for COVID-19 Market Challenges Table 157. Specific Antiviral Drugs for COVID-19 Market Restraints Table 158. Research Programs/Design for This Report Table 159. Key Data Information from Secondary Sources Table 160. Key Data Information from Primary Sources List of Figures Figure 1. Global Specific Antiviral Drugs for COVID-19 Market Share by Type in 2022 & 2028 Figure 2. Tablet Features Figure 3. Injection Features Figure 4. Global Specific Antiviral Drugs for COVID-19 Market Share by Application in 2022 & 2028 Figure 5. Mild Symptom Patient Case Studies Figure 6. Critically Ill Patient Case Studies Figure 7. Specific Antiviral Drugs for COVID-19 Report Years Considered Figure 8. Global Specific Antiviral Drugs for COVID-19 Market Size and Growth Rate (2022-2028) (US$ Million) Figure 9. Global Specific Antiviral Drugs for COVID-19 Market Share by Regions (2022-2028) Figure 10. Global Specific Antiviral Drugs for COVID-19 Market Share by Players in 2021 Figure 11. Global Specific Antiviral Drugs for COVID-19 Market Size Market Share by Type (2022-2028) Figure 12. Global Specific Antiviral Drugs for COVID-19 Market Size Market Share by Application (2022-2028) Figure 13. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application in 2021 Figure 14. North America Specific Antiviral Drugs for COVID-19 Market Size 2022-2028 (US$ Million) Figure 15. Europe Specific Antiviral Drugs for COVID-19 Market Size 2022-2028 (US$ Million) Figure 16. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size 2022-2028 (US$ Million) Figure 17. Specific Antiviral Drugs for COVID-19 Market Size in Latin America (2022-2028) (US$ Million) Figure 18. Specific Antiviral Drugs for COVID-19 Market Size in Middle East & Africa (2022-2028) (US$ Million) Figure 19. Bottom-up and Top-down Approaches for This Report Figure 20. Data Triangulation Figure 21. Key Executives Interviewed

Sanofi Novartis Shanghai Zhongxisanwei Teva Zydus Cadila Mylan Apotex Advanz Pharma Sun Pharma Kyung Poong Ipca Laboratories Hanlim Pharmaceutical Bristol Laboratories Bayer Rising Pharmaceutical Shanghai Pharma Sichuan Sunny Hope Guangzhou Baiyunshan Guanghua Pharmaceutical CSPC Group KPC Group Jinghua Pharmaceutical Group Zhongsheng Pharma North China Pharmaceutical Group